Tag: Dementia

Certified Dementia Practitioner Amy Schenk joins Suzanne from Cape Coral, Florida, courtesy of Athira Pharma to talk about the impacts of the pandemic on families and people with Alzheimer’s disease. Amy also educates in both Assisted Living and Long Term Care environments.

Athira Pharma has a clinical trial right now for patients that potentially could treat people with any type of degenerative brain disease. It is being tested now with people who have Alzheimer's disease in mid stages and also with people who have Lewy body disease and Parkinson's disease. The medication speeds up thinking and processing and a long-term effect of increasing connections between brain cells. Suzanne Newman talks with Dr. Michael Mega, Director of the Center for Cognitive Health in Portland, Oregon. The center helps patients maximize their cognitive function as they cope with Alzheimer's disease and disorders of thinking.

This segment focuses on medical diagnoses for Alzheimer's disease, Lewy body dementia and Parkinson's. The field is rapidly changing. We now have biological markers for Alzheimer's: mis-folded proteins in the brain is the common thread for all degenerative diseases, including Parkinson's disease, Lou Gehrig's disease, and frontotemporal degeneration Pick's Disease. Being able to visualize these in PET scans (Positron Emission Tomography) lets us make a definitive diagnosis 15 years before someone begins having memory problems.

Suzanne Newman is joined by Dr. Michael Mega, Director of the Center for Cognitive Health in Portland, Oregon. Dr. Mega answers: How do you tell the difference between normal age-related forgetfulness and the beginnings of Alzheimer's?

This segment focuses on misconceptions of clinical trials and who qualifies for the Lewy body dementia clinical trial. Dr. Daniel Burdick, a physician's investigator at Evergreen Hospital Medical Center in Kirkland, Washington, covers these topics with Suzanne Newman.

This segment focuses on what doctors test in the Lewy body dementia clinical trial, as well as the importance of the study participant's care partner. Dr. Daniel Burdick walks Suzanne Newman through these aspects of the clinical trial. In the shape trial, doctors are looking at elements of safety and efficacy. Safety issues include studying bloodwork, physical exams, and checking things like changes in mood. The efficacy of the medication is studied by assessing the participant's cognition: the person's ability to remember, recall, fluidly use words, retain their focus and comprehension, and plan and follow events. They'll be asked to recall words and draw figures, and these are compared from the beginning to the end of the trial. Doctors also measure brain waves with EEG to get more objective data than they can from asking questions.

This segment focuses on what it means to be involved in the Lewy body dementia shape trial. Dr. Daniel Burdick, a physician's investigator at Evergreen Hospital Medical Center in Kirkland, Washington walks Suzanne Newman through the process. Participating in a clinical trial is a donation of time to the global effort to develop better treatments for Parkinson's disease and Dementia with Lewy Bodies. It can be involved. This particular trial is a 6-8 month process with 9 or 10 visits to the Kirkland site, one every 4-6 weeks, each one a couple to several hours each, with doctors spending lots of time with them. Doctors ask detailed questions and get to know their experiences in much greater detail, and people have said that it's a positive experience because they feel really connected. A research coordinator becomes their navigator through the trial.

Dr. Daniel Burdick from the Evergreen Hospital Medical Center in Kirkland, Washington, joins Suzanne to talk about Lewy body dementia. It encompasses two separate disorders: Parkinson's dementia and Dementia with Lewy Bodies, which are very similar. One of the best ways to make your future better, if you have dementia, if you want to be proactive with the disease, is to volunteer in a clinical trial.

Allyson Schrier, co-founder of Zinnia TV, talks about what's next for the streaming service optimized for people who are living with dementia and Alzheimer's:...

Allyson Schrier, co-founder of Zinnia TV, talks about the reasons why she developed a streaming service optimized for people who are living with dementia...